2UZO
Crystal structure of human CDK2 complexed with a thiazolidinone inhibitor
Summary for 2UZO
| Entry DOI | 10.2210/pdb2uzo/pdb |
| Related | 1AQ1 1B38 1B39 1BUH 1CKP 1DI8 1DM2 1E1V 1E1X 1E9H 1F5Q 1FIN 1FQ1 1FVT 1FVV 1G5S 1GIH 1GII 1GIJ 1GY3 1GZ8 1H00 1H01 1H07 1H08 1H0V 1H0W 1H1P 1H1Q 1H1R 1H1S 1H24 1H25 1H26 1H27 1H28 1HCK 1HCL 1JST 1JSU 1JSV 1JVP 1KE5 1KE6 1KE7 1KE8 1KE9 1OGU 1OI9 1OIQ 1OIR 1OIT 1OIU 1OIY 1OKV 1OKW 1OL1 1OL2 1P2A 1P5E 1PF8 1PKD 1PW2 1PXI 1PXJ 1PXK 1PXL 1PXM 1PXN 1PXO 1PXP 1PYE 1QMZ 1R78 1URC 1URW 1V1K 1VYW 1VYZ 1W0X 1W8C 1W98 1WCC 1Y8Y 1Y91 1YKR 2A0C 2A4L 2B52 2B53 2B54 2B55 2BHE 2BHH 2BKZ 2BPM 2BTR 2BTS 2C4G 2C5N 2C5O 2C5P 2C5T 2C5V 2C5X 2C5Y 2C68 2C69 2C6I 2C6K 2C6L 2C6M 2C6O 2C6T 2CCH 2CCI 2CJM 2CLX 2EXM 2IW6 2IW8 2IW9 2J9M 2JGZ 2UUE 2UZB 2UZD 2UZE 2UZL 2UZN |
| Descriptor | CELL DIVISION PROTEIN KINASE 2, 4-{5-[(Z)-(2,4-DIOXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE (3 entities in total) |
| Functional Keywords | transferase, atp-binding, phosphorylation, cdk2, kinase, cyclin, mitosis, cell cycle, cell division, nucleotide-binding, serine/threonine-protein kinase, thiazolidinone ligand |
| Biological source | HOMO SAPIENS (HUMAN) |
| Total number of polymer chains | 1 |
| Total formula weight | 34326.86 |
| Authors | Richardson, C.M.,Dokurno, P.,Murray, J.B.,Surgenor, A.E. (deposition date: 2007-04-30, release date: 2007-06-26, Last modification date: 2023-12-13) |
| Primary citation | Richardson, C.M.,Nunns, C.L.,Williamson, D.S.,Parratt, M.J.,Dokurno, P.,Howes, R.,Borgognoni, J.,Drysdale, M.J.,Finch, H.,Hubbard, R.E.,Jackson, P.S.,Kierstan, P.,Lentzen, G.,Moore, J.D.,Murray, J.B.,Simmonite, H.,Surgenor, A.E.,Torrance, C.J. Discovery of a Potent Cdk2 Inhibitor with a Novel Binding Mode, Using Virtual Screening and Initial, Structure-Guided Lead Scoping. Bioorg.Med.Chem.Lett., 17:3880-, 2007 Cited by PubMed Abstract: Virtual screening against a pCDK2/cyclin A crystal structure led to the identification of a potent and novel CDK2 inhibitor, which exhibited an unusual mode of interaction with the kinase binding motif. With the aid of X-ray crystallography and modelling, a medicinal chemistry strategy was implemented to probe the interactions seen in the crystal structure and to establish SAR. A fragment-based approach was also considered but a different, more conventional, binding mode was observed. Compound selectivity against GSK-3beta was improved using a rational design strategy, with crystallographic verification of the CDK2 binding mode. PubMed: 17570665DOI: 10.1016/J.BMCL.2007.04.110 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.3 Å) |
Structure validation
Download full validation report
